FDA Draft Guidance for the Use of Bayesian Methods in Clinical Trials

JAMA 2026

View at publisher
Authors: Andrew Gelman, Erik van Zwet, Witold Więcek
DOI: 10.1001/jama.2026.4178
Cited by: 5
References: 2

Abstract

This Perspective discusses the draft guidance for industry that the US Food and Drug Administration released on the use of bayesian methods in testing therapeutics.

Fields of Study & Subjects

Statistical Methods in Clinical Trials Advanced Causal Inference Techniques Statistical Methods and Bayesian Inference

Publication details

Journal / source
JAMA
Publisher
American Medical Association (AMA)
Volume
335
Issue
19
Pages
1662–1662
Publication date
23 March 2026
Language
EN